Press Release Details
Unum Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, MA, November 29, 2016 – Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that President and Chief Executive Officer Chuck Wilson will present at the 28th Annual Piper Jaffray Healthcare Conference on November 30, 2016 at 11:30 am ET. The conference is being held at the Lotte New York Palace in New York.
Unum Therapeutics
Unum uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The Company’s lead program, which combines Unum’s proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with rituximab, is in Phase 1 clinical testing to assess its safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.
###
Media Contact:
Unum Therapeutics Inc.
Jeff Michaels
+1-617-843-3820
Corporate_Communications@unumrx.com